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Fingolimod (FTY720, Gilenya®, Novartis Pharma AG, Basel, Switzerland) is a sphingosin-1-25 
phosphate (S1P) receptor modulator with immunomodulatory properties, which traps naïve 26 
and central memory T cells in lymph nodes leading to reduced numbers of peripheral blood 27 
lymphocytes, and is the first licensed oral drug for multiple sclerosis (MS) (1, 2). We here 28 
report a case of a near fatal herpes simplex virus 1 (HSV-1) encephalitis under the licensed 29 
dose of fingolimod in a MS patient. 30 
A 38 year-old male was diagnosed with relapsing-remitting MS in 2007. In 2007 he entered 31 
the TRANSFORMS phase 3 study comparing fingolimod (0.5 or 1.5mg daily) with with 32 
interferon beta 1a (Avonex®, Biogen Idec, Cambridge, USA) and placebo. Since 08/2008 he 33 
participated in the TRANSFORMS extension study and received fingolimod (1.25 or 0.5mg) 34 
and from 04/2010 he continued with 0.5mg (Umbrella). In 03/2013, he had minor deficits with 35 
an EDSS (expanded disability status score(3)) of 2.5 (which ranges from 0 to 10, with higher 36 
scores indicating greater disability and 10 = death from MS). From 2007 – 2013 the patient 37 
suffered only from one MS relapse and showed EDSS worsening from 1.5 – 2.5. 38 
In 04/2014, he was admitted to the emergency department with loss of consciousness, fever 39 
and epileptic seizures. Cranial computed tomography (CT) showed a hypodense area in the 40 
right temporal lobe (figure 1A). Diagnosis of HSV-1 encephalitis was made by PCR from 41 
cerebrospinal fluid (CSF) showing 216.721 HSV-1 DNA copies/ml, 10 cells/µl and total 42 
protein of 0.519 g/l. Blood count showed lymphopenia of 410 cells/µl. Anti-HSV-1 IgG 43 
antibodies were already positive at presentation in serum and CSF, while anti-HSV-1 IgM 44 
and ani-HSV-2 antibodies remained negative. The medical history mentioned a previous 45 
herpes labialis. Antiviral therapy with intravenous aciclovir was initiated immediately at the 46 
day of presentation at the standard dose. Cranial magnetic resonance imaging (MRI) showed 47 
signs of non-hemorrhagic encephalitis of archecortical areas of both hemispheres (figure 48 
1B). 49 
After 34 days, the patient was referred to a neurological rehabilitation center. At discharge he 50 
was alert, showed signs of right dominant tetraparesis and was unable to speak due to a 51 
tracheal cannula, resulting in an EDSS of 9.5 indicating severe disability. Follow-up 52 
examinations in the next 9 months showed clinical worsening and progressive brain atrophy 53 
accentuated in the post-encephalitic regions (figures 1C and 1D).  54 
Despite its potent immunomodulatory effects leading to reduced circulating lymphocyte 55 
counts fingolimod did not lead to increased rates of severe infections in clinical phase 3 56 
studies (1, 2, 4). Only immunity against herpes viruses with CNS latency, especially varicella 57 
zoster virus (VZV) and HSV, shows subtle impairments. This has been shown by two cases, 58 
who died from fatal infections during 1.25mg fingolimod and additional course of 59 
corticosteroids for MS relapse treatment in one phase 3 study (2). Furthermore, a second 60 
phase 3 study showed an increased rate of VZV infections (4), whereas no increase in 61 
herpes virus infections was seen in a third phase 3 study (1). Our patient had not received 62 
corticosteroids or other immunomodulatory treatments apart from fingolimod, the only co-63 
medication was buproprion, Wellbutrin®, GlaxoSmithKline AG, Münchenbuchsee, 64 
Switzerland and occasionally methylphenidate (Ritalin®, Novartis Pharma AG, Basel, 65 
Switzerland). Prior to onset of HSV-1 encephalitis he had not shown any evidence for 66 
immunologically relevant co-morbidities during continuous follow-up in our MS outpatient 67 
clinic since 2007. Beside these rare and fatal cases a recent study reported that fingolimod 68 
treatment of MS patients lowers VZV-specific immunity and suggested that subclinical VZV 69 
reactivation, demonstrated by PCR detection of VZV DNA in the saliva, is higher among 70 
patients treated with fingolimod compared with healthy controls (5). 71 
Different from other immunomodulatory drugs that can compromise specific aspects of 72 
immune control fingolimod treatment may lead to a subtle, but in some cases clinically 73 
relevant compromise of immune responses against herpes viruses that stay in their latent 74 
stages in the nervous system compartment, i.e. VZV and HSV-1, while immune responses 75 
against those that reside in immune organs (CMV and EBV) appear unaffected. In order to 76 
try to avoid serious adverse events it will be important to understand these interactions 77 
better. 78 
By reporting this case of HSV-1 encephalitis under 0.5mg fingolimod we want to stress the 79 
importance of further studies on how fingolimod impairs immunity against HSV-1 and VZV to 80 
prevent such severe complications in the future. 81 
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Figure Legend 1: Neuroimaging 85 
A: Cranial CT scan at the day of admission (coronarl, left, and axial slices, right) shows a hypodense 86 
area of the right temporal lobe. 87 
B: MRI scan of the brain (coronarl slices left, axial slices right, depicted are FLAIR sequences) shows 88 
hypodense areas of archecortical structures and the right temporal lobe. The follow-up MRI scans 4 89 
months (C) and 9 months (D) show progressive and wide-spread leukencephalopathy. Depicted are 90 
coronal (left) and axial (right) slices of FLAIR sequences. The positioning of the head the scanner 91 
differs, partially related to agitation of the patient during the examination. All scans are performed and 92 
kindly provided by the Department of Neuroradiology, University Hospital Zurich, Switzerland.  93 
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